Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis
(2019) In Translational Research 212. p.67-79- Abstract
Pancreatic cancer is an aggressive malignancy that carries a high mortality rate. A major contributor to the poor outcome is the lack of effective molecular markers. The purpose of this study was to develop protein markers for improved prognostication and noninvasive diagnosis. A mass spectrometry (MS)-based discovery approach was applied to pancreatic cancer tissues and healthy pancreas. In the verification phase, extracellular proteins with differential expression were further quantified in targeted mode using parallel reaction monitoring (PRM). Next, a tissue microarray (TMA) cohort including 140 pancreatic cancer resection specimens was constructed, in order to validate protein expression status and investigate potential prognostic... (More)
Pancreatic cancer is an aggressive malignancy that carries a high mortality rate. A major contributor to the poor outcome is the lack of effective molecular markers. The purpose of this study was to develop protein markers for improved prognostication and noninvasive diagnosis. A mass spectrometry (MS)-based discovery approach was applied to pancreatic cancer tissues and healthy pancreas. In the verification phase, extracellular proteins with differential expression were further quantified in targeted mode using parallel reaction monitoring (PRM). Next, a tissue microarray (TMA) cohort including 140 pancreatic cancer resection specimens was constructed, in order to validate protein expression status and investigate potential prognostic implications. The levels of protein candidates were finally assessed in a prospective series of 110 serum samples in an accredited clinical laboratory using the automated Cobas system. Protein sequencing with nanoliquid chromatography tandem MS (nano-LC-MS/MS) and targeted PRM identified alpha-1-acid glycoprotein 1 (AGP1) as an upregulated protein in pancreatic cancer tissue. Using TMA and immunohistochemistry, AGP1 expression was significantly associated with shorter overall survival (HR = 2.22; 95% CI 1.30–3.79, P = 0.004). Multivariable analysis confirmed the results (HR = 1.87; 95% CI 1.08–3.24, P = 0.026). Circulating levels of AGP1 yielded an area under the curve (AUC) of 0.837 for the discrimination of resectable pancreatic cancer from healthy controls. Combining AGP1 with CA 19-9 enhanced the diagnostic performance, with an AUC of 0.963. This study suggests that AGP1 is a novel prognostic biomarker in pancreatic cancer tissue. Serum AGP1 levels may be useful as part of a biomarker panel for early detection of pancreatic cancer but further studies are needed.
(Less)
- author
- Zhou, Q. LU ; Andersson, Roland LU ; Hu, Dingyuan LU ; Bauden, Monika LU ; Sasor, A. LU ; Bygott, Thomas ; PawŁowski, Krzysztof LU ; Pla, Indira LU ; Marko-Varga, György LU and Ansari, Daniel LU
- organization
- publishing date
- 2019-06-29
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Translational Research
- volume
- 212
- pages
- 13 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85068769496
- pmid:31295437
- ISSN
- 1931-5244
- DOI
- 10.1016/j.trsl.2019.06.003
- language
- English
- LU publication?
- yes
- id
- f7ad7eaa-c76c-4e71-b9d4-c840b40fa574
- alternative location
- https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068769496&doi=10.1016%2fj.trsl.2019.06.003&partnerID=40&md5=cbaf7668c5e8ca1a4aa97c9c706ed94f
- date added to LUP
- 2019-07-24 10:55:33
- date last changed
- 2024-04-16 16:54:01
@article{f7ad7eaa-c76c-4e71-b9d4-c840b40fa574, abstract = {{<p>Pancreatic cancer is an aggressive malignancy that carries a high mortality rate. A major contributor to the poor outcome is the lack of effective molecular markers. The purpose of this study was to develop protein markers for improved prognostication and noninvasive diagnosis. A mass spectrometry (MS)-based discovery approach was applied to pancreatic cancer tissues and healthy pancreas. In the verification phase, extracellular proteins with differential expression were further quantified in targeted mode using parallel reaction monitoring (PRM). Next, a tissue microarray (TMA) cohort including 140 pancreatic cancer resection specimens was constructed, in order to validate protein expression status and investigate potential prognostic implications. The levels of protein candidates were finally assessed in a prospective series of 110 serum samples in an accredited clinical laboratory using the automated Cobas system. Protein sequencing with nanoliquid chromatography tandem MS (nano-LC-MS/MS) and targeted PRM identified alpha-1-acid glycoprotein 1 (AGP1) as an upregulated protein in pancreatic cancer tissue. Using TMA and immunohistochemistry, AGP1 expression was significantly associated with shorter overall survival (HR = 2.22; 95% CI 1.30–3.79, P = 0.004). Multivariable analysis confirmed the results (HR = 1.87; 95% CI 1.08–3.24, P = 0.026). Circulating levels of AGP1 yielded an area under the curve (AUC) of 0.837 for the discrimination of resectable pancreatic cancer from healthy controls. Combining AGP1 with CA 19-9 enhanced the diagnostic performance, with an AUC of 0.963. This study suggests that AGP1 is a novel prognostic biomarker in pancreatic cancer tissue. Serum AGP1 levels may be useful as part of a biomarker panel for early detection of pancreatic cancer but further studies are needed.</p>}}, author = {{Zhou, Q. and Andersson, Roland and Hu, Dingyuan and Bauden, Monika and Sasor, A. and Bygott, Thomas and PawŁowski, Krzysztof and Pla, Indira and Marko-Varga, György and Ansari, Daniel}}, issn = {{1931-5244}}, language = {{eng}}, month = {{06}}, pages = {{67--79}}, publisher = {{Elsevier}}, series = {{Translational Research}}, title = {{Alpha-1-acid glycoprotein 1 is upregulated in pancreatic ductal adenocarcinoma and confers a poor prognosis}}, url = {{http://dx.doi.org/10.1016/j.trsl.2019.06.003}}, doi = {{10.1016/j.trsl.2019.06.003}}, volume = {{212}}, year = {{2019}}, }